drugset / Trial / NCT05020782
The BeLimumab Antiphospholipid Syndrome Trial (BLAST)
NaSingle-groupOpen-labelTreatment
Summary
AIM: The primary objective of the BeLimumab Antiphospholipid Syndrome Trial (BLAST) is to evaluate the safety and tolerability of belimumab for up to 24 months in patients with persistent aPL positivity and clinical features attributable to aPL that are resistant to warfarin and/or heparin.
Timeline
- Start
- 2022-06-01
- Primary completion
- 2024-10-01
- Completion
- 2025-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belimumab | Monoclonal antibody | 10 mg/kg | — |